THE SCHEDULE 13D

Company

Kymera Therapeutics, Inc.

Filed

August 25, 2020

Accession Number

0000921895-20-002327

A Schedule 13D is filed when an investor acquires more than 5% of a company's shares with an intent to influence control. Learn more about SC 13D filings →